Lv61
1760 积分 2024-06-11 加入
AA噁男
Defining the Treatment Window: Early Versus Late Pulsed Dye Laser Therapy for Posttraumatic and Surgical Scars in Asian Patients
22天前
已完结
Overview of Peptides and Their Potential Roles in Skin Health and Beauty
4个月前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]
7个月前
已完结
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
7个月前
已完结
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
7个月前
已关闭
Three-year B/F/TAF use in treatmentnaive (TN) and treatment-experienced (TE) PLWH in the BICSTaR study in Canada, France and Germany
7个月前
已完结
Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
7个月前
已完结
Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
7个月前
已关闭
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
7个月前
已完结
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
7个月前
已完结
皖公网安备34019202002308
